Table 3.
Novel formulations for intratympanic delivery that have entered clinical development.
| Drug | Active pharmaceutical ingredient | Therapeutic class | Indication | Drug delivery system | Clinical status |
|---|---|---|---|---|---|
| OTIPRIO | Ciprofloxacin | Antibacterial | Otitis media with effusion undergoing tympanostomy tube placement Acute otitis externa | Poloxamer | FDA approved |
| OTIVIDEX | Dexamethasone | Steroid | Vertigo associated with Meniere’s disease | Poloxamer | Phase III |
| AM-101 | S-Ketamine | NMDA antagonist | Tinnitus | Hyaluronic acid | Phase III |
| AM-111 | D-JNKI-1 | JNK inhibitor | Hearing loss | Hyaluronic acid | Phase III |
| FX-322 | Progenitor Cell Activation | Several | Hearing loss | Poloxamer | Phase I/II |
| OTO-311 | Gacyclidine | NMDA antagonist | Tinnitus | Poloxamer | Phase I |